Metyrapone Clinical Trials

Size	Price	Qty
25mg	USD 97
1g	USD 970

Clinical Trials

Numerous clinical trials evaluate metyrapone across Early Phase 1 through Phase 4 for indications including Cushing's syndrome, autonomous cortisol secretion, major depressive disorder, cocaine and tobacco use disorders, and obesity-related metabolic dysfunction. Sponsored by academic medical centers, government bodies like the National Institute on Drug Abuse, and pharmaceutical companies including GlaxoSmithKline and Embera NeuroTherapeutics, these studies evaluate both safety and efficacy. Their recruitment statuses encompass completed, active not recruiting, recruiting, not yet recruiting, and unknown status, reflecting sustained clinical interest in modulating cortisol synthesis.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07138274	NOT_YET_RECRUITING	Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS)	Mayo Clinic	2026-08	PHASE2
NCT07494084	NOT_YET_RECRUITING	Shift Work Schedule; Circadian Rhythm; Insulin Resistance; Circadian Misalignment	Washington State University	2026-07-01	PHASE4
NCT06106295	ACTIVE_NOT_RECRUITING	Autonomous Cortisol Secretion; Mild Autonomous Cortisol Secretion (MACS)	Mayo Clinic	2023-12-19	PHASE2
NCT07268222	RECRUITING	Mild Autonomous Cortisol Secretion (MACS)	Laikο General Hospital, Athens	2025-12-01	PHASE4
NCT06556277	COMPLETED	Glucocorticoids; Overweight and Obesity; Overeating	Eleonora Seelig	2024-09-01
NCT06801249	RECRUITING	Adrenal Incidentalomas; Cushing Syndrome	IRCCS Azienda Ospedaliero-Universitaria di Bologna	2021-02-23	PHASE4
NCT05919992	COMPLETED	Glucocorticoid Effect	Eleonora Seelig	2023-05-15	EARLY_PHASE1
NCT05167084	COMPLETED	Glucocorticoid Effect	Eleonora Seelig	2022-02-08	EARLY_PHASE1
NCT03491696	UNKNOWN	Depressive Disorder; Hormone Disturbance	Centre Hospitalier Rouffach	2018-12-22	PHASE4
NCT02297945	COMPLETED	Cushing's Syndrome	HRA Pharma	2015-04	PHASE3
NCT03491696	Unknown status	Depressive Disorder\|Hormone Disturbance	Centre Hospitalier Rouffach\|University Hospital Strasbourg France	2018-12-22	Phase 4
NCT01673087	COMPLETED	Stress	University of Michigan	2012-10	PHASE1
NCT02856854	COMPLETED	Cocaine Use Disorder	Embera NeuroTherapeutics, Inc.	2016-07	PHASE1
NCT02368379	COMPLETED	Prader Willi Syndrome; Adrenal Insufficiency	Nationwide Children's Hospital	2014-03
NCT02406066	COMPLETED	Cocaine Use Disorder; Tobacco Use Disorder	Embera NeuroTherapeutics, Inc.	2015-03	PHASE1
NCT02406066	Completed	Cocaine Use Disorder\|Tobacco Use Disorder	Embera NeuroTherapeutics Inc.\|National Institute on Drug Abuse (NIDA)	2015-03	Phase 1
NCT01620684	UNKNOWN	Metabolic Syndrome; Obesity; Insulin Resistance	Baker Heart Research Institute	2013-02	PHASE4
NCT01375920	COMPLETED	Depression	Jane Barnes	2011-02	PHASE3
NCT00567814	COMPLETED	Cocaine Dependence; Cocaine Addiction	Embera NeuroTherapeutics, Inc.	2007-12
NCT00426608	COMPLETED	Depressive Disorder and Anxiety Disorders	GlaxoSmithKline	2006-10-06	PHASE1
NCT00125554	COMPLETED	Major Depressive Disorder	Universitätsklinikum Hamburg-Eppendorf	1998-05	PHASE2
NCT00033098	UNKNOWN	Cocaine-Related Disorders; Infusions, Intravenous	National Institute on Drug Abuse (NIDA)	2001-11	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-29)

Check the Metyrapone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Metyrapone selectively binds to and inhibits steroid 11-beta-monooxygenase (CYP11B1), blocking the enzymatic conversion of 11-deoxycortisol to cortisol within the adrenal cortex. This targeted suppression of adrenal steroid synthesis decreases circulating systemic cortisol levels, providing clinical utility in controlling hypercortisolism in Cushing's syndrome and modulating stress-response pathways in major depressive disorder and substance use disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).